首页 > 最新文献

Gynecological Endocrinology最新文献

英文 中文
The in vitro mechanism of Vaspinregulates the proliferation and steroidogenesis of rat lutein cells. Vaspin调节大鼠黄体细胞增殖和类固醇生成的体外机制。
IF 2 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-05-10 DOI: 10.1080/09513590.2024.2351525
Xiao-Wen Fu, Ling Liu, Xiao-Yu Zhu, Jian-Jun Wang

Objective: Stable luteal cell function is an important prerequisite for reproductive ability and embryonic development. However, luteal insufficiency seriously harms couples who have the desire to have a pregnancy, and the most important thing is that there is no complete solution. In addition, Vaspin has been shown to have regulatory effects on luteal cells, but the complex mechanisms involved have not been fully elucidated. Therefore, this study aimed to explore the effect of Vaspin on rat luteal cells and its mechanism.

Methods: Granulosa lutein cells separated from the ovary of female rats were incubated for 24h with gradient concentrations of Vaspin, and granulosa lutein cells incubated with 0.5% bovine serum albumin were used as controls. The proliferation, apoptosis, angiogenesis, progesterone (P4) and estradiol (E2) were detected by CCK-8, Anneixn-FITC/PI staining, angiogenesis experiment and ELISA. Western blot was applied to observe the expression levels of proteins related to cell proliferation, apoptosis, angiogenesis and MEK/MAPK signaling pathway.

Results: Compared with the Control group, Vaspin could significantly up-regulate the proliferation of granulosa lutein cells and reduce the apoptosis. Moreover, Vaspin promoted the angiogenesis of granulosa lutein cells and the production of P4 and E2 in a concentration-dependent manner. Furthermore, Vaspin up-regulated the CyclinD1, CyclinB1, Bcl2, VEGFA and FGF-2 expression in granulosa lutein cells, and down-regulated the level of Bax. Also, Vaspin increased the p-MEK1 and p-p38 levels.

Conclusion: Vaspin can up-regulate the proliferation and steroidogenesis of rat luteal cells and reduce apoptosis, which may be related to the influence of MEK/MAPK activity.

目的:稳定的黄体细胞功能是生殖能力和胚胎发育的重要前提:稳定的黄体细胞功能是生殖能力和胚胎发育的重要前提。然而,黄体功能不全严重危害着有怀孕愿望的夫妇,最重要的是没有彻底的解决办法。此外,Vaspin 已被证明对黄体细胞具有调节作用,但其中的复杂机制尚未完全阐明。因此,本研究旨在探讨Vaspin对大鼠黄体细胞的影响及其机制:方法:将从雌性大鼠卵巢中分离出的颗粒黄体细胞与梯度浓度的Vaspin培养24小时,以0.5%牛血清白蛋白培养的颗粒黄体细胞为对照。通过CCK-8、Anneixn-FITC/PI染色、血管生成实验和ELISA等方法检测增殖、凋亡、血管生成、孕酮(P4)和雌二醇(E2)。采用 Western blot 检测细胞增殖、凋亡、血管生成和 MEK/MAPK 信号通路相关蛋白的表达水平:结果:与对照组相比,Vaspin能显著上调颗粒黄素细胞的增殖并减少其凋亡。此外,Vaspin还能促进颗粒黄体细胞的血管生成,并以浓度依赖的方式促进P4和E2的产生。此外,Vaspin 还能上调颗粒黄体细胞中 CyclinD1、CyclinB1、Bcl2、VEGFA 和 FGF-2 的表达,并下调 Bax 的水平。此外,Vaspin还能提高p-MEK1和p-p38的水平:结论:Vaspin能上调大鼠黄体细胞的增殖和类固醇生成,减少细胞凋亡,这可能与MEK/MAPK活性的影响有关。
{"title":"The <i>in vitro</i> mechanism of Vaspinregulates the proliferation and steroidogenesis of rat lutein cells.","authors":"Xiao-Wen Fu, Ling Liu, Xiao-Yu Zhu, Jian-Jun Wang","doi":"10.1080/09513590.2024.2351525","DOIUrl":"https://doi.org/10.1080/09513590.2024.2351525","url":null,"abstract":"<p><strong>Objective: </strong>Stable luteal cell function is an important prerequisite for reproductive ability and embryonic development. However, luteal insufficiency seriously harms couples who have the desire to have a pregnancy, and the most important thing is that there is no complete solution. In addition, Vaspin has been shown to have regulatory effects on luteal cells, but the complex mechanisms involved have not been fully elucidated. Therefore, this study aimed to explore the effect of Vaspin on rat luteal cells and its mechanism.</p><p><strong>Methods: </strong>Granulosa lutein cells separated from the ovary of female rats were incubated for 24h with gradient concentrations of Vaspin, and granulosa lutein cells incubated with 0.5% bovine serum albumin were used as controls. The proliferation, apoptosis, angiogenesis, progesterone (P4) and estradiol (E2) were detected by CCK-8, Anneixn-FITC/PI staining, angiogenesis experiment and ELISA. Western blot was applied to observe the expression levels of proteins related to cell proliferation, apoptosis, angiogenesis and MEK/MAPK signaling pathway.</p><p><strong>Results: </strong>Compared with the Control group, Vaspin could significantly up-regulate the proliferation of granulosa lutein cells and reduce the apoptosis. Moreover, Vaspin promoted the angiogenesis of granulosa lutein cells and the production of P4 and E2 in a concentration-dependent manner. Furthermore, Vaspin up-regulated the CyclinD1, CyclinB1, Bcl2, VEGFA and FGF-2 expression in granulosa lutein cells, and down-regulated the level of Bax. Also, Vaspin increased the p-MEK1 and p-p38 levels.</p><p><strong>Conclusion: </strong>Vaspin can up-regulate the proliferation and steroidogenesis of rat luteal cells and reduce apoptosis, which may be related to the influence of MEK/MAPK activity.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2351525"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between female sexual function and metabolic features of the polycystic ovary syndrome in Turkish women of reproductive age. 土耳其育龄妇女的女性性功能与多囊卵巢综合征代谢特征之间的关系。
IF 2 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-06-24 DOI: 10.1080/09513590.2024.2362249
Meral Cevik Dogan, Tevfik Yoldemir

Objective: To investigate the association between female sexual function and metabolic features among women with polycystic ovary syndrome (PCOS) during reproductive age.

Method: This was a cross-sectional study in which 288 women with PCOS and 180 women without PCOS between the ages of 20 and 40 years were evaluated. All women had serum total testosterone, androstenedione, DHEA-S, fasting glucose, total cholesterol, HDL-C, LDL-C, and triglyceride levels analyzed. The McCoy Female Sexual Questionnaire (MFSQ) was applied to all studied women. Exploratory factor analysis and reliability analysis were done after data collection. The factor loadings of MFSQ domains were compared between women with PCOS and controls.

Results: Average factor loadings of the MFSQ sexuality domain and MFSQ sexual partner domain were significantly lower in the PCOS group when compared to controls. There was no correlation between the two sexual function domains of the MFSQ and the PCOS features either in the PCOS group or the controls.

Conclusion: PCOS is a heterogeneous disease with different metabolic components, such as insulin resistance, obesity, and hyperandrogenism. Although sexual function among women with PCOS was lower than controls, no differences were found in metabolic features of the PCOS and non-PCOS groups with relation to sexual function determined by the MFSQ.

目的研究育龄期多囊卵巢综合征(PCOS)女性性功能与代谢特征之间的关系:这是一项横断面研究,对年龄在 20 至 40 岁之间的 288 名多囊卵巢综合征女性和 180 名非多囊卵巢综合征女性进行了评估。对所有女性的血清总睾酮、雄烯二酮、DHEA-S、空腹血糖、总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和甘油三酯水平进行了分析。麦考伊女性性问卷调查表(MFSQ)适用于所有接受研究的女性。数据收集后进行了探索性因子分析和可靠性分析。比较了多囊卵巢综合症妇女和对照组妇女的 MFSQ 领域因子载荷:结果:与对照组相比,多囊卵巢综合症组的 MFSQ 性生活领域和 MFSQ 性伴侣领域的平均因子负荷明显较低。在多囊卵巢综合症组和对照组中,MFSQ 的两个性功能领域与多囊卵巢综合症特征之间均无相关性:结论:多囊卵巢综合征是一种异质性疾病,具有不同的代谢成分,如胰岛素抵抗、肥胖和高雄激素。虽然多囊卵巢综合征妇女的性功能低于对照组,但在根据 MFSQ 测定的性功能方面,多囊卵巢综合征组和非多囊卵巢综合征组的代谢特征并无差异。
{"title":"The association between female sexual function and metabolic features of the polycystic ovary syndrome in Turkish women of reproductive age.","authors":"Meral Cevik Dogan, Tevfik Yoldemir","doi":"10.1080/09513590.2024.2362249","DOIUrl":"https://doi.org/10.1080/09513590.2024.2362249","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association between female sexual function and metabolic features among women with polycystic ovary syndrome (PCOS) during reproductive age.</p><p><strong>Method: </strong>This was a cross-sectional study in which 288 women with PCOS and 180 women without PCOS between the ages of 20 and 40 years were evaluated. All women had serum total testosterone, androstenedione, DHEA-S, fasting glucose, total cholesterol, HDL-C, LDL-C, and triglyceride levels analyzed. The McCoy Female Sexual Questionnaire (MFSQ) was applied to all studied women. Exploratory factor analysis and reliability analysis were done after data collection. The factor loadings of MFSQ domains were compared between women with PCOS and controls.</p><p><strong>Results: </strong>Average factor loadings of the MFSQ sexuality domain and MFSQ sexual partner domain were significantly lower in the PCOS group when compared to controls. There was no correlation between the two sexual function domains of the MFSQ and the PCOS features either in the PCOS group or the controls.</p><p><strong>Conclusion: </strong>PCOS is a heterogeneous disease with different metabolic components, such as insulin resistance, obesity, and hyperandrogenism. Although sexual function among women with PCOS was lower than controls, no differences were found in metabolic features of the PCOS and non-PCOS groups with relation to sexual function determined by the MFSQ.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2362249"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Concern: Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. 表达关切:用非那雄胺和氟他胺治疗多囊卵巢综合征妇女的多毛症。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-11-26 DOI: 10.1080/09513590.2024.2429857
{"title":"Expression of Concern: Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome.","authors":"","doi":"10.1080/09513590.2024.2429857","DOIUrl":"https://doi.org/10.1080/09513590.2024.2429857","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2429857"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (Goserelin acetate) 10.8 mg prior to surgery in Chinese premenopausal women with symptomatic uterine fibroids.
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1080/09513590.2024.2427190
Yanchun Liang, Ruyu Yang, Yajing Wei, Biqi Huang, Youguo Chen, Xinmei Zhang, Jilong Yao, Guoyun Wang, Hongluan Mao, Honghui Shi, Qing Yang, Junying Tang, Mei Ji, Keqin Hua, Shuzhong Yao

Objectives: To assess the effect and safety of Zoladex (Goserelin acetate) 10.8 mg in patients with uterine fibroids.

Methods: Fifty-three patients received Goserelin acetate 10.8 mg once and surgery was conducted at 12 weeks ± 7 days after drug injection. All assessments form baseline to week12/before surgery were carried out: fibroids volume, uterine volume, serum hormone (E2, FSH, LH), hemoglobin concentration, uterine arterial resistance index (UA-RI), fibroid arterial RI (FA-RI) and improvements of symptoms (Uterine Fibroid Symptom and Quality of Life (UFS-QOL) and Health-Related Quality of Life (HRQL) scores). Adverse events (AEs) were recorded to evaluate the safety.

Results: After 12 weeks of treatment, the volume of uterine fibroids was significantly smaller than before (249.19 ± 297.04 vs. 195.77 ± 418.27 cm3, p < 0.0001). The volume of the uterus was also smaller than before (372.02 vs. 263.58 cm3, p < 0.0001). Serum levels of E2, FSH, and LH showed significant decreasing trend (61.13 pmol/L, 5.23 IU/L and 4.75 IU/L respectively, p < 0.0001) and hemoglobin levels were increased significantly (108.30 ± 26.28 VS. 134.90 ± 9.21g/L, p < 0.0001). Left and right UA-RI showed slight increase of 0.04 and 0.02 respectively from baseline without significance. Mean FA-RI showed slight decrease of 0.03 from baseline (p = 0.22). Patient symptoms were alleviated after treatment. In addition, AEs occurred in 81.1% of enrolled patients and all AEs were well tolerably.

Conclusions: Goserelin acetate 10.8 mg pretreatment can effectively reduce the volume of uterine fibroids and uterus, lower estrogen levels and improve anemia symptoms. It could also improve the quality of life of patients, showing good safety and tolerance. This pretreatment was effective, safe, and generally well tolerated.

{"title":"Multicenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (Goserelin acetate) 10.8 mg prior to surgery in Chinese premenopausal women with symptomatic uterine fibroids.","authors":"Yanchun Liang, Ruyu Yang, Yajing Wei, Biqi Huang, Youguo Chen, Xinmei Zhang, Jilong Yao, Guoyun Wang, Hongluan Mao, Honghui Shi, Qing Yang, Junying Tang, Mei Ji, Keqin Hua, Shuzhong Yao","doi":"10.1080/09513590.2024.2427190","DOIUrl":"https://doi.org/10.1080/09513590.2024.2427190","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the effect and safety of Zoladex (Goserelin acetate) 10.8 mg in patients with uterine fibroids.</p><p><strong>Methods: </strong>Fifty-three patients received Goserelin acetate 10.8 mg once and surgery was conducted at 12 weeks ± 7 days after drug injection. All assessments form baseline to week12/before surgery were carried out: fibroids volume, uterine volume, serum hormone (E2, FSH, LH), hemoglobin concentration, uterine arterial resistance index (UA-RI), fibroid arterial RI (FA-RI) and improvements of symptoms (Uterine Fibroid Symptom and Quality of Life (UFS-QOL) and Health-Related Quality of Life (HRQL) scores). Adverse events (AEs) were recorded to evaluate the safety.</p><p><strong>Results: </strong>After 12 weeks of treatment, the volume of uterine fibroids was significantly smaller than before (249.19 ± 297.04 vs. 195.77 ± 418.27 cm3, <i>p</i> < 0.0001). The volume of the uterus was also smaller than before (372.02 vs. 263.58 cm3, <i>p</i> < 0.0001). Serum levels of E2, FSH, and LH showed significant decreasing trend (61.13 pmol/L, 5.23 IU/L and 4.75 IU/L respectively, <i>p</i> < 0.0001) and hemoglobin levels were increased significantly (108.30 ± 26.28 VS. 134.90 ± 9.21g/L, <i>p</i> < 0.0001). Left and right UA-RI showed slight increase of 0.04 and 0.02 respectively from baseline without significance. Mean FA-RI showed slight decrease of 0.03 from baseline (<i>p</i> = 0.22). Patient symptoms were alleviated after treatment. In addition, AEs occurred in 81.1% of enrolled patients and all AEs were well tolerably.</p><p><strong>Conclusions: </strong>Goserelin acetate 10.8 mg pretreatment can effectively reduce the volume of uterine fibroids and uterus, lower estrogen levels and improve anemia symptoms. It could also improve the quality of life of patients, showing good safety and tolerance. This pretreatment was effective, safe, and generally well tolerated.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2427190"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardization for ovarian tissue cryopreservation and transplantation in China.
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 DOI: 10.1080/09513590.2024.2431223
Xiangyan Ruan

Ovarian tissue cryopreservation and transplantation is one of the most advanced and promising fertility preservation methods. Prior to any procedure that may lead to a toxic ovarian injury (such as chemotherapy or radiotherapy), a portion of the ovary is removed and cryopreserved. At an appropriate time, after toxic therapy is concluded, the cryopreserved ovarian tissue is then thawed and transplanted back to the patient when conditions permit. This technique can not only preserve female fertility but also restore ovarian endocrine function. However, there is no standardization for ovarian tissue cryopreservation and transplantation in China. In order to promote the standardized development of ovarian tissue cryopreservation technology in the whole country, it is urgent to establish the standard of this technology.

{"title":"Standardization for ovarian tissue cryopreservation and transplantation in China.","authors":"Xiangyan Ruan","doi":"10.1080/09513590.2024.2431223","DOIUrl":"10.1080/09513590.2024.2431223","url":null,"abstract":"<p><p>Ovarian tissue cryopreservation and transplantation is one of the most advanced and promising fertility preservation methods. Prior to any procedure that may lead to a toxic ovarian injury (such as chemotherapy or radiotherapy), a portion of the ovary is removed and cryopreserved. At an appropriate time, after toxic therapy is concluded, the cryopreserved ovarian tissue is then thawed and transplanted back to the patient when conditions permit. This technique can not only preserve female fertility but also restore ovarian endocrine function. However, there is no standardization for ovarian tissue cryopreservation and transplantation in China. In order to promote the standardized development of ovarian tissue cryopreservation technology in the whole country, it is urgent to establish the standard of this technology.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2431223"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arm muscle area is correlated to handgrip strength in postmenopausal women. 绝经后妇女的手臂肌肉面积与握力相关。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-11-01 DOI: 10.1080/09513590.2024.2420937
Ludwig R Álvarez-Córdova, Reyes Artacho, Peter Chedraui, Cecilia Arteaga-Pazmiño, Melissa Sánchez-Briones, María D Ruiz-López

Objective: To analyze the correlation between arm muscle area and handgrip strength among postmenopausal community dwelling low-income women in order to provide an easy anthropometric indicator to assess muscle mass quantity and quality.

Methods: This was a cross-sectional study involving postmenopausal women (n = 171) from three urban-marginal communities of Guayaquil, Ecuador. Corrected arm muscle area was calculated using the Frisancho formula. Dynapenia was defined as HGS < 16 kg. Spearman's correlation coefficient was calculated at a 5% significance level to test the correlation between corrected arm muscle area and handgrip strength.

Results: Median (interquartile range: IQR) age of the sample was 72.0 years (17.0). The median of corrected arm muscle area was 34.8 cm2 (20.7). The overall prevalence of dynapenia was 57.9% (n = 99). There was a significant decreasing trend with age regarding all anthropometric characteristics and handgrip strength, as well as a higher prevalence of dynapenia with age. For the whole sample, a statistically significant positive correlation was found between corrected arm muscle area and handgrip strength [r = 0.267; p < .001].

There was a significant yet weak positive correlation between corrected arm muscle area and handgrip strength in this postmenopausal sample. There is a need for additional research in this regard.

目的分析绝经后社区低收入妇女手臂肌肉面积与握力之间的相关性,为评估肌肉质量和数量提供一个简便的人体测量指标:这是一项横断面研究,涉及厄瓜多尔瓜亚基尔市三个城市边缘社区的绝经后妇女(n = 171)。采用 Frisancho 公式计算校正手臂肌肉面积。HGS<16千克定义为 "动力不足"。斯皮尔曼相关系数的显著性水平为 5%,用于检验校正臂肌面积与握力之间的相关性:样本年龄中位数(四分位间距:IQR)为 72.0 岁(17.0)。矫正臂肌面积的中位数为 34.8 平方厘米(20.7)。动态肌无力症的总发病率为 57.9%(n = 99)。随着年龄的增长,所有人体测量特征和握力都呈明显的下降趋势,而随着年龄的增长,动态肌无力症的患病率也有所上升。在整个样本中,校正手臂肌肉面积与握力之间存在统计学意义上的显著正相关[r = 0.267; p 在这个绝经后样本中,校正手臂肌肉面积与握力之间存在显著但微弱的正相关。在这方面还需要进行更多的研究。
{"title":"Arm muscle area is correlated to handgrip strength in postmenopausal women.","authors":"Ludwig R Álvarez-Córdova, Reyes Artacho, Peter Chedraui, Cecilia Arteaga-Pazmiño, Melissa Sánchez-Briones, María D Ruiz-López","doi":"10.1080/09513590.2024.2420937","DOIUrl":"https://doi.org/10.1080/09513590.2024.2420937","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the correlation between arm muscle area and handgrip strength among postmenopausal community dwelling low-income women in order to provide an easy anthropometric indicator to assess muscle mass quantity and quality.</p><p><strong>Methods: </strong>This was a cross-sectional study involving postmenopausal women (<i>n</i> = 171) from three urban-marginal communities of Guayaquil, Ecuador. Corrected arm muscle area was calculated using the Frisancho formula. Dynapenia was defined as HGS < 16 kg. Spearman's correlation coefficient was calculated at a 5% significance level to test the correlation between corrected arm muscle area and handgrip strength.</p><p><strong>Results: </strong>Median (interquartile range: IQR) age of the sample was 72.0 years (17.0). The median of corrected arm muscle area was 34.8 cm<sup>2</sup> (20.7). The overall prevalence of dynapenia was 57.9% (<i>n</i> = 99). There was a significant decreasing trend with age regarding all anthropometric characteristics and handgrip strength, as well as a higher prevalence of dynapenia with age. For the whole sample, a statistically significant positive correlation was found between corrected arm muscle area and handgrip strength [<i>r</i> = 0.267; <i>p</i> < .001].</p><p><p>There was a significant yet weak positive correlation between corrected arm muscle area and handgrip strength in this postmenopausal sample. There is a need for additional research in this regard.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2420937"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SIRT2-dependent DKK1 deacetylation aggravates polycystic ovary syndrome by targeting the TGF-β1/Smad3 signaling pathway. SIRT2依赖的DKK1去乙酰化通过靶向TGF-β1/Smad3信号通路加重多囊卵巢综合征。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-05-31 DOI: 10.1080/09513590.2024.2353733
Lan Chen, Caixia Kong

Background: Polycystic ovarian syndrome (PCOS) is a prevalent metabolic and endocrine condition in females of reproductive age. This work was to discover the underlying role of Dickkopf 1 (DKK1) and its putative regulating mechanism in P COS.

Methods: Mice recieved dehydroepiandrosterone (DHEA) injection to establish the in vivo P COS model.Hematoxylin and eosin (H&E) staining was performed for histological analysis. RT-qP CR and Western blotting were used to detect gene and protein expression. CCK-8 and flow cytometry assays were applied to detect cell viability and apoptosis. Co-immunoprecipitation (Co-IP) and immunoprecipitation (IP) were applied to assess association between DKK1 and SIRT2.

Results: In this work, DKK1 is downregulated in P COS rats. It was revealed that DKK1 knockdown induced apoptosis and suppressed proliferation in KGN cells, whereas DKK1 overexpression had exactly the opposite effects. In addition, DKK1 deactivates the T GF-β1/SMad3 signaling pathway, thereby controlling KGN cell proliferation and apoptosis. Besides, SIRT2 inhibition reversed the impact of DKK1 overexpression on KGN cell proliferation and apoptosis. Furthermore, SIRT2 downregulated DKK1 expression by deacetylating DKK1 in KGN cells.

Discussion: Altogether, we concluded that SIRT2-induced deacetylation of DKK1 triggers T GF-β1/Smad3 hyperactivation, thereby inhibiting proliferation and promoting apoptosis of KGN cells. The above results indicated that DKK1 might function as a latent target for P COS treatment.

背景:多囊卵巢综合征(PCOS)是育龄女性普遍存在的一种代谢和内分泌疾病。本研究旨在发现 Dickkopf 1 (DKK1) 在多囊卵巢综合征中的潜在作用及其调控机制:小鼠注射脱氢表雄酮(DHEA)以建立体内 P COS 模型。采用 RT-qP CR 和 Western 印迹法检测基因和蛋白质的表达。CCK-8 和流式细胞术检测细胞活力和凋亡。共免疫沉淀(Co-IP)和免疫沉淀(IP)用于评估 DKK1 和 SIRT2 之间的关联:结果:在这项工作中,DKK1在P COS大鼠中被下调。结果:该研究发现,DKK1在P COS大鼠中被下调,DKK1敲除会诱导KGN细胞凋亡并抑制其增殖,而DKK1过表达则会产生相反的效果。此外,DKK1还能使T GF-β1/SMad3信号通路失活,从而控制KGN细胞的增殖和凋亡。此外,抑制SIRT2可逆转DKK1过表达对KGN细胞增殖和凋亡的影响。此外,SIRT2通过使DKK1在KGN细胞中去乙酰化而下调DKK1的表达:总之,我们认为SIRT2诱导的DKK1去乙酰化会引发T GF-β1/Smad3过度激活,从而抑制KGN细胞的增殖并促进其凋亡。上述结果表明,DKK1可能是P COS治疗的潜在靶点。
{"title":"SIRT2-dependent DKK1 deacetylation aggravates polycystic ovary syndrome by targeting the TGF-β1/Smad3 signaling pathway.","authors":"Lan Chen, Caixia Kong","doi":"10.1080/09513590.2024.2353733","DOIUrl":"10.1080/09513590.2024.2353733","url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovarian syndrome (PCOS) is a prevalent metabolic and endocrine condition in females of reproductive age. This work was to discover the underlying role of Dickkopf 1 (DKK1) and its putative regulating mechanism in P COS.</p><p><strong>Methods: </strong>Mice recieved dehydroepiandrosterone (DHEA) injection to establish the <i>in vivo</i> P COS model.Hematoxylin and eosin (H&E) staining was performed for histological analysis. RT-qP CR and Western blotting were used to detect gene and protein expression. CCK-8 and flow cytometry assays were applied to detect cell viability and apoptosis. Co-immunoprecipitation (Co-IP) and immunoprecipitation (IP) were applied to assess association between DKK1 and SIRT2.</p><p><strong>Results: </strong>In this work, DKK1 is downregulated in P COS rats. It was revealed that DKK1 knockdown induced apoptosis and suppressed proliferation in KGN cells, whereas DKK1 overexpression had exactly the opposite effects. In addition, DKK1 deactivates the T GF-β1/SMad3 signaling pathway, thereby controlling KGN cell proliferation and apoptosis. Besides, SIRT2 inhibition reversed the impact of DKK1 overexpression on KGN cell proliferation and apoptosis. Furthermore, SIRT2 downregulated DKK1 expression by deacetylating DKK1 in KGN cells.</p><p><strong>Discussion: </strong>Altogether, we concluded that SIRT2-induced deacetylation of DKK1 triggers T GF-β1/Smad3 hyperactivation, thereby inhibiting proliferation and promoting apoptosis of KGN cells. The above results indicated that DKK1 might function as a latent target for P COS treatment.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2353733"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The drospirenone only pill as a contraceptive option for breastfeeding women: First data on users' acceptability and newborn development. 作为哺乳期妇女避孕选择的只含屈螺酮的避孕药:关于使用者接受度和新生儿发育的首批数据。
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-07-29 DOI: 10.1080/09513590.2024.2382800
Pedro Antonio Regidor, Enrico Colli, Artur Jakimiuk

Background: Progestin-only pills (POPs) have been used for contraception in breastfeeding women for years. The existing guidelines allow the use of these contraceptives.

Methods: Multicenter study with a single visit and retrospective data review. The study involved 100 women who used a drospirenone-only pill (DRSP) for contraception for at least 5 months during breastfeeding. The study aimed to analyze for those successful users the impact on new-born development, the bleeding profile and evaluate user satisfaction.

Results: Analysis of the newborns showed that their growth parameters length and weight, were within the expected range of standard development. The mean birth weight was 3368 g, with the lowest recorded weight being 2860 g and the highest 5040 g. The median length of the newborns was 55 cm, ranging from 35 to 65 cm. All new-borns demonstrated appropriate growth within the established percentiles. Acceptability with the bleeding profile was rated with a VAS score: the mean acceptability rating was 82.8. Women aged 35 years or older reported significantly higher acceptability compared to younger women (≥35 years: mean = 88.4, SD = 16.5; <35 years: mean = 80.3, SD = 20.2) (p = 0.02). Sixty-one patients (N = 61; 61.0%; 95% CI: 50.7 - 70.4%) expressed willingness to continue using DRSP after breastfeeding.

Conclusion: Among those patients who continued the use of the DRSP only-pill for 5 months, this study shows no negative impact for new-borns, with no clinical influence observed on their growth. Additionally, those users expressed high satisfaction with the bleeding profile of the pill.Clinical trial registration number: DRKS00028438 .

背景:纯孕激素避孕药(POPs)多年来一直用于哺乳期妇女的避孕。现行指南允许使用这些避孕药物:方法:采用单次访问和回顾性数据审查的多中心研究。该研究涉及 100 名在哺乳期使用屈螺酮避孕药(DRSP)避孕至少 5 个月的妇女。研究旨在分析这些成功使用者对新生儿发育、出血情况的影响,并评估使用者的满意度:结果:对新生儿的分析表明,他们的身长和体重等生长参数都在标准发育的预期范围内。平均出生体重为 3368 克,最低为 2860 克,最高为 5040 克。新生儿身长的中位数为 55 厘米,从 35 厘米到 65 厘米不等。所有新生儿都在既定的百分位数范围内适当生长。出血情况的可接受性由 VAS 评分来评定:平均可接受性评分为 82.8 分。与年轻女性相比,35 岁或以上女性的可接受性明显更高(≥35 岁:平均值 = 88.4,标准差 = 16.5;P = 0.02)。61名患者(N = 61;61.0%;95% CI:50.7 - 70.4%)表示愿意在哺乳后继续使用 DRSP:结论:本研究表明,在继续使用 DRSP 单一药片 5 个月的患者中,新生儿没有受到任何负面影响,他们的发育也没有受到临床影响。此外,使用者对药片的出血情况表示非常满意:DRKS00028438 .
{"title":"The drospirenone only pill as a contraceptive option for breastfeeding women: First data on users' acceptability and newborn development.","authors":"Pedro Antonio Regidor, Enrico Colli, Artur Jakimiuk","doi":"10.1080/09513590.2024.2382800","DOIUrl":"https://doi.org/10.1080/09513590.2024.2382800","url":null,"abstract":"<p><strong>Background: </strong>Progestin-only pills (POPs) have been used for contraception in breastfeeding women for years. The existing guidelines allow the use of these contraceptives.</p><p><strong>Methods: </strong>Multicenter study with a single visit and retrospective data review. The study involved 100 women who used a drospirenone-only pill (DRSP) for contraception for at least 5 months during breastfeeding. The study aimed to analyze for those successful users the impact on new-born development, the bleeding profile and evaluate user satisfaction.</p><p><strong>Results: </strong>Analysis of the newborns showed that their growth parameters length and weight, were within the expected range of standard development. The mean birth weight was 3368 g, with the lowest recorded weight being 2860 g and the highest 5040 g. The median length of the newborns was 55 cm, ranging from 35 to 65 cm. All new-borns demonstrated appropriate growth within the established percentiles. Acceptability with the bleeding profile was rated with a VAS score: the mean acceptability rating was 82.8. Women aged 35 years or older reported significantly higher acceptability compared to younger women (≥35 years: mean = 88.4, SD = 16.5; <35 years: mean = 80.3, SD = 20.2) (<i>p</i> = 0.02). Sixty-one patients (<i>N</i> = 61; 61.0%; 95% CI: 50.7 - 70.4%) expressed willingness to continue using DRSP after breastfeeding.</p><p><strong>Conclusion: </strong>Among those patients who continued the use of the DRSP only-pill for 5 months, this study shows no negative impact for new-borns, with no clinical influence observed on their growth. Additionally, those users expressed high satisfaction with the bleeding profile of the pill.Clinical trial registration number: DRKS00028438 .</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2382800"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical. 人类羊膜上皮细胞在卵巢早衰中的应用:从临床前到临床
IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-12-01 Epub Date: 2024-07-22 DOI: 10.1080/09513590.2024.2382818
Xiaojing Zhao, Zhongna Yu, Xinrun Wang, Xiaojing Li, Yang Liu, Liang Wang

Premature ovarian insufficiency (POI) or premature ovarian failure (POF) is a multifactorial disorder occurring in reproductive-age women, characterized by elevated levels of follicle-stimulating hormone (FSH) and irregular or absent menstrual cycles, often accompanied by perimenopausal symptoms and infertility. While assisted reproductive technology can address the reproductive aspirations of some POI-affected women, it is hindered by issues such as exorbitant expenses, substantial risks, and poor rates of conception. Encouragingly, extensive research is exploring novel approaches to enhance fertility, particularly in the realm of stem cell therapy, showcasing both feasibility and significant potential. Human amniotic epithelial cells (hAECs) from discarded placental tissues are crucial in regenerative medicine for their pluripotency, low immunogenicity, non-tumorigenicity, accessibility, and minimal ethical concerns. Preclinical studies highlight the underlying mechanisms and therapeutic effects of hAECs in POI treatment, and current research is focusing on innovative interventions to augment hAECs' efficacy. However, despite these strides, overcoming application challenges is essential for successful clinical translation. This paper conducted a comprehensive analysis of the aforementioned issues, examining the prospects and challenges of hAECs in POI, with the aim of providing some insights for future research and clinical practice.

卵巢功能早衰(POI)或卵巢早衰(POF)是发生在育龄妇女身上的一种多因素疾病,其特征是卵泡刺激素(FSH)水平升高、月经周期不规律或缺失,通常伴有围绝经期症状和不孕症。虽然辅助生殖技术可以满足一些受 POI 影响的妇女的生殖愿望,但它受到诸如高昂的费用、巨大的风险和低受孕率等问题的阻碍。令人鼓舞的是,广泛的研究正在探索提高生育能力的新方法,特别是在干细胞疗法领域,显示出可行性和巨大潜力。从废弃胎盘组织中提取的人类羊膜上皮细胞(hAECs)具有多能性、低免疫原性、非致癌性、易获取性和最小的伦理问题,因此在再生医学中至关重要。临床前研究强调了 hAECs 在 POI 治疗中的潜在机制和治疗效果,目前的研究重点是创新性干预措施,以增强 hAECs 的疗效。然而,尽管取得了这些进展,但要成功实现临床转化,克服应用挑战至关重要。本文对上述问题进行了全面分析,探讨了 hAECs 在 POI 中的应用前景和挑战,旨在为未来的研究和临床实践提供一些启示。
{"title":"The administration of human amniotic epithelial cells in premature ovarian insufficiency: From preclinical to clinical.","authors":"Xiaojing Zhao, Zhongna Yu, Xinrun Wang, Xiaojing Li, Yang Liu, Liang Wang","doi":"10.1080/09513590.2024.2382818","DOIUrl":"https://doi.org/10.1080/09513590.2024.2382818","url":null,"abstract":"<p><p>Premature ovarian insufficiency (POI) or premature ovarian failure (POF) is a multifactorial disorder occurring in reproductive-age women, characterized by elevated levels of follicle-stimulating hormone (FSH) and irregular or absent menstrual cycles, often accompanied by perimenopausal symptoms and infertility. While assisted reproductive technology can address the reproductive aspirations of some POI-affected women, it is hindered by issues such as exorbitant expenses, substantial risks, and poor rates of conception. Encouragingly, extensive research is exploring novel approaches to enhance fertility, particularly in the realm of stem cell therapy, showcasing both feasibility and significant potential. Human amniotic epithelial cells (hAECs) from discarded placental tissues are crucial in regenerative medicine for their pluripotency, low immunogenicity, non-tumorigenicity, accessibility, and minimal ethical concerns. Preclinical studies highlight the underlying mechanisms and therapeutic effects of hAECs in POI treatment, and current research is focusing on innovative interventions to augment hAECs' efficacy. However, despite these strides, overcoming application challenges is essential for successful clinical translation. This paper conducted a comprehensive analysis of the aforementioned issues, examining the prospects and challenges of hAECs in POI, with the aim of providing some insights for future research and clinical practice.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2382818"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of growth hormone therapy on the onset and progression of pubertal development in girls with idiopathic short stature. 生长激素疗法对特发性矮身材女孩青春期发育的起始和进展的影响。
IF 2 4区 医学 Q2 Medicine Pub Date : 2024-12-01 Epub Date: 2024-05-28 DOI: 10.1080/09513590.2024.2358227
Feng Zhu, Qi Xu, Lingxiao Huang, Jieqian Zhu, Lina Huang, Yu Zhang

Objective: The aim of this study was to explore the impact of growth hormone (GH) therapy on the onset and progression of puberty in girls with idiopathic short stature.

Methods: This study included 541 girls aged between 4.5 and 10.6 years who were receiving GH treatment, monitored over a 22-year follow-up period. Of these, 126 girls have been followed up to the onset of menarche. The participants were divided into two groups: a ISS control group (n = 66) and a group receiving daily GH treatment at a dose of 0.15 iu/kg (n = 60). We assessed the pubertal development and GH usage of these girls every three months.

Results: (1) There was no significant difference in the onset of puberty between the growth hormone (GH) treatment group and the control group; however, the average duration of puberty was longer in the treatment group compared to the control group. (2) During puberty, there were no significant differences in height growth between the treated and untreated groups. (3) The duration of GH treatment showed a significant negative correlation with the age at onset of gonadal development and the age at menarche in females within the treatment group.

Conclusion: GH treatment does not seem to accelerate the onset of puberty but may extend its duration, without significantly impacting height growth during puberty. Additionally, longer GH treatment duration is linked to earlier gonadal development and menarche in females.

研究目的本研究旨在探讨生长激素(GH)疗法对特发性矮身材女孩青春期的发生和发展的影响:这项研究包括 541 名年龄在 4.5 岁至 10.6 岁之间、正在接受生长激素治疗的女孩,对她们进行了长达 22 年的跟踪监测。其中,126 名女孩一直跟踪到月经初潮。参与者被分为两组:ISS对照组(66人)和每天接受0.15 iu/kg剂量GH治疗组(60人)。结果:(1)生长激素(GH)治疗组与对照组的青春期开始时间无显著差异;但治疗组的青春期平均持续时间比对照组长。(2)在青春期,治疗组和未治疗组的身高增长没有明显差异。(3) GH 治疗持续时间与治疗组女性性腺开始发育的年龄和初潮年龄呈显著负相关:结论:GH 治疗似乎不会加速青春期的到来,但可能会延长青春期的持续时间,而不会对青春期的身高增长产生重大影响。此外,延长 GH 治疗时间还与女性性腺发育和初潮年龄提前有关。
{"title":"Effects of growth hormone therapy on the onset and progression of pubertal development in girls with idiopathic short stature.","authors":"Feng Zhu, Qi Xu, Lingxiao Huang, Jieqian Zhu, Lina Huang, Yu Zhang","doi":"10.1080/09513590.2024.2358227","DOIUrl":"10.1080/09513590.2024.2358227","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to explore the impact of growth hormone (GH) therapy on the onset and progression of puberty in girls with idiopathic short stature.</p><p><strong>Methods: </strong>This study included 541 girls aged between 4.5 and 10.6 years who were receiving GH treatment, monitored over a 22-year follow-up period. Of these, 126 girls have been followed up to the onset of menarche. The participants were divided into two groups: a ISS control group (<i>n</i> = 66) and a group receiving daily GH treatment at a dose of 0.15 iu/kg (<i>n</i> = 60). We assessed the pubertal development and GH usage of these girls every three months.</p><p><strong>Results: </strong>(1) There was no significant difference in the onset of puberty between the growth hormone (GH) treatment group and the control group; however, the average duration of puberty was longer in the treatment group compared to the control group. (2) During puberty, there were no significant differences in height growth between the treated and untreated groups. (3) The duration of GH treatment showed a significant negative correlation with the age at onset of gonadal development and the age at menarche in females within the treatment group.</p><p><strong>Conclusion: </strong>GH treatment does not seem to accelerate the onset of puberty but may extend its duration, without significantly impacting height growth during puberty. Additionally, longer GH treatment duration is linked to earlier gonadal development and menarche in females.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2358227"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141161894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gynecological Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1